Advertisement

Journal of Neuro-Oncology

, Volume 142, Issue 2, pp 319–325 | Cite as

Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression

  • D. Ryan OrmondEmail author
  • B. K. Kleinschmidt-DeMasters
  • Daniel Cavalcante
  • Elizabeth E. Smith
  • Scott D. Cramer
  • M. Scott Lucia
Clinical Study

Abstract

Background

Prostatic carcinoma metastatic to dura is commonly encountered at autopsy, but presenting as a dural or, especially parenchymal, brain metastasis during life is far less common. Our group has been interested in two immunohistochemical (IHC) markers previously shown to be downregulated in particularly aggressive primary prostatic carcinomas: CHD1 and MAP3K7. Here we assess protein expression in clinically-relevant CNS metastases. We also assessed how these two markers correlated with the most common genetic alteration in prostate cancer: TMPRSS2 fusion to ERG (40–60% of carcinomas at the primary site), which places ERG expression under the control of the androgen-regulated TMPRSS2 gene, increasing expression.

Design

Database query, 2000–2016, identified 16 metastases to dura, 5 to brain parenchyma.

Results

Four of five intraparenchymal metastases and 15/16 informative dural-based metastases were ERG-negative (90.5% overall). There was reduced expression of CHD1 in 8/21 and reduced MAP3K7 in 17/21 cases; 7/19 (37%) ERG-negative metastases had dual low expression of CHD1/MAP3K7. ERG-positive cases had high expression of one or both markers.

Conclusion

Metastatic prostatic carcinoma to CNS demonstrates expression patterns consistent with particularly aggressive behavior. Lower ERG expression in dural and intraparenchymal metastases suggests a possibility that ERG-negative tumors with loss of MAP3K7 may become resistant to standard therapies and diffusely metastasize.

Keywords

Prostate cancer Brain metastasis Dural metastasis ERG CHD1 MAP3K7 

Notes

Acknowledgements

We are grateful to Ms. Lisa Litzenberger for her assistance with photography and figure construction.

Author Contributions

DRO was involved in research design, data collection, and writing and editing the manuscript. BKK-D was involved in research design, data collection, and writing and editing the manuscript. DC was involved in data collection. EES was involved in data collection and writing the manuscript, SDC was involved with rationale and writing and editing of the manuscript. MSL was involved in data collection, and writing and editing the manuscript.

Funding

Author SDC was funded by R01-CA199741.

Compliance with ethical standards

Conflict of interest

Dr. Ormond does, however, have unrelated research funded by Synaptive Medical. The authors declare no conflict of interest related to this project.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Hatzoglou V, Patel G, Morris M, Curtis K, Zhang Z, Shi W, Huse J, Rosenblum M, Holodny A, Young R (2014) Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis. J Neuroimaging 24:161–166CrossRefGoogle Scholar
  2. 2.
    Tremont-Lukats I, Bobustuc G, Lagos G, Lolas K, Kyritsis A, Pudavalli V (2003) Brain metastasis from prostate carcinoma: the M. D. Anderson Cancer Center experience. Cancer 98:363–368CrossRefGoogle Scholar
  3. 3.
    Teng L-H, Wang C, Begin L, Dolph M, Yilmaz A, Trpkov K, Donnelly B, Bismar T (2013) ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease. Urology 82:394–399CrossRefGoogle Scholar
  4. 4.
    Guo C, Wang Y, Xiao L, Troncoso P, Czerniak B (2012) The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers. Human Pathol 43:644–649CrossRefGoogle Scholar
  5. 5.
    Abou-Ouf H, Zhao L, Bismar T (2016) ERG expression in prostate cancer: biological relevance and clinical implication. J Cancer Res Clin Oncol 142:1781–1793CrossRefGoogle Scholar
  6. 6.
    Gsponer J, Braun M, Scheble V, Zellweger T, Bachmann A, Perner S, Vlajnic T, Srivastava M, Tan S, Dobi A, Sesterhenn I, Srivastava S, Bubendorf L, Ruiz C (2014) ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 17:126–131CrossRefGoogle Scholar
  7. 7.
    Rodrigues L, Rider L, Nieto C, Romero L, Karimpour-Fard A, Loda M, Lucia M, Wu M, Shi L, Cimic A, Sirintrapun S, Nolley R, Pac C, Chen H, Peehl D, Xu J, Liu W, Costello J, Cramer S (2015) Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res 75:1021–1034CrossRefGoogle Scholar
  8. 8.
    Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL (2018) Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 15:222–234CrossRefGoogle Scholar
  9. 9.
    Mudd P, Hohensee S, Lillehei K, Kingdom T, Kleinschmidt-DeMasters B (2012) Ectopic pituitary adenoma of the clivus presenting with apoplexy: case report and review of the literature. Clin Neuropathol 31:24–30CrossRefGoogle Scholar
  10. 10.
    Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH, Zadra G, Penney KL, Mosquera JM, Tyekucheva S, Mucci LA, Barbieri C, Loda M (2018) Genetic and epigenetic determinants of aggressiveness in cribriform carcinoma of the prostate. Mol Cancer Res.  https://doi.org/10.1158/1541-7786.MCR-18-0440 Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NeurosurgeryUniversity of Colorado School of MedicineAuroraUSA
  2. 2.Department of PathologyUniversity of Colorado School of MedicineAuroraUSA
  3. 3.Department of NeurologyUniversity of Colorado School of MedicineAuroraUSA
  4. 4.Department of PharmacologyUniversity of Colorado School of MedicineAuroraUSA
  5. 5.Department of NeurosurgeryUniversity of Colorado School of MedicineAuroraUSA

Personalised recommendations